(Hong Kong, Decenber 10, 2019) The leading transcatheter heart valve medical device player in China - Venus Medtech (Hangzhou) Inc. (“Venus Medtech” or the “Company”, stock code: 2500), has successfully listed and commenced dealings on the Main Board of the Stock Exchange of Hong Kong Limited ( “Hong Kong Stock Exchange”) today, with a board lot of 500 H Shares. The share price closed at HK$43.05 with an intra-day high of HK$43.5 per share, up approximatly 31% compared with the final offer price of HK$33 per share. A total of approximately 5.29 millions shares were traded, with an aggregate turnover of approximately HK$2.1 billion.

Mr. Min Frank Zeng, Chairman of the Board of Directors and Executive Director of Venus Medtech (Hangzhou) Inc., said, “Getting listed on the Hong Kong Stock Exchange is an important milestone in the Company’s development. We are honored to receive enthusiastic support from all our investors. Venus Medtech strives to become a global leader in the development and commercialization of transcatheter solutions for structural heart diseases. In the future, we will continue to grow sales of VenusA-Valve and leverage our experience with VenusA-Valve to commercialize VenusP-Valve and other product candidates in China. In addition, we will expand our presence in North America, the EU and emerging markets to become a global leader, continue to advance and strengthen our pipeline products within the structural heart disease space, and further enhance the position in the industry.”

Mr. Min Frank Zeng concluded, “The successful listing of Venus Medtech (Hangzhou) Inc. on the Hong Kong Stock Exchange today has started a new chapter in the Company’s development. We will leverage on the advantageous resources from Hong Kong’s capital market, give full play to our competitive edges, enhance our core competitiveness, and explore new business opportunities and markets, with a view to providing better investment returns for our shareholders.’’